계명대학교 의학도서관 Repository

Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study).

Metadata Downloads
Author(s)
Keun-Ho ParkMyung Ho JeongYoung Joon HongYoungkeun AhnHyun Kuk KimYoung Yub KohDoo Il KimSang Wook KimWeon KimJay Young RhewJong Seon ParkHun Sik ParkJang Ho BaeJang-Whan BaeSeok Kyu OhSung Yun LeeSeung Wook LeeJae Hwan LeeSang Yeob LimJang Hyun ChoKwang Soo ChaJai Keon ChaeSeung Ho HurSun Ho HwangJin Yong HwangSeung Woon Rha
Keimyung Author(s)
Hur, Seung HoSon, Chang Nam
Department
Dept. of Internal Medicine (내과학)
Journal Title
Yonsei Medical Journal
Issued Date
2018
Volume
59
Issue
1
Keyword
Biolimus-eluting stentacute coronary syndromebiodegradable polymer
Abstract
PURPOSE:

This study sought to determine the 1-year clinical effectiveness and safety of a biodegradable, polymer-containing Biolimus A9™-eluting stent (BES) in Korean patients with acute coronary syndrome (ACS).

MATERIALS AND METHODS:

A total of 1000 ACS patients with 1251 lesions who underwent implantation of BESs at 22 centers in Korea were enrolled between May 2011 and July 2013. We assessed major adverse cardiac events (MACE) defined as the composite of cardiac death, non-fatal myocardial infarction (MI), and clinical-driven target vessel revascularization at 12 months.

RESULTS:

Patient mean age was 62.6±11.4 years. 72.8% of the patients were male, 28.5% had diabetes, 32.8% had multi-vessel disease (MVD), and 47.9% presented with acute MI (AMI). The mean global registry of acute coronary events risk score of all patients was 103.0±27.6. The number of stents per patient was 1.3±0.6. The incidences of MACE and definite stent thrombosis at 12 months were 3.9% and 0.2%, respectively. On multivariate Cox-regression analysis, age ≥65 years was identified as an independent predictors of 1-year MACE (hazard ratio=2.474; 95% confidence interval=1.202-5.091). Subgroup analyses revealed no significant differences in the incidence of MACE between patients with and without diabetes (4.3% vs. 3.7%, p=0.667), between those who presented with and without AMI (4.4% vs. 3.4%, p=0.403), and between those with and without MVD (4.6% vs. 3.5%, p=0.387).

CONCLUSION:

Our study demonstrated excellent 1-year clinical outcomes of BES implantation in patients at low-risk for ACS.
Keimyung Author(s)(Kor)
허승호
손창남
Publisher
School of Medicine (의과대학)
Citation
Keun-Ho Park et al. (2018). Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study). Yonsei Medical Journal, 59(1), 72–79. doi: 10.3349/ymj.2018.59.1.72
Type
Article
ISSN
0513-5796
DOI
10.3349/ymj.2018.59.1.72
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41211
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.